MENU
Go to the list of all blogs
published in Blogs
Aug 21, 2024

Immuno-Oncology Sector Performance and Ticker Analysis

The immuno-oncology sector, comprising companies that develop advanced technologies for cancer treatment, has shown promising performance recently. This sector's innovation and critical role in advancing cancer treatments have led to a significant market response, reflected in a notable +8.04% increase in performance over the past week. Below is an analysis of the key players in this group—Corvus Pharmaceuticals (CRVS), AnaptysBio (ANAB), and iTeos Therapeutics (ITOS)—focusing on market capitalization, price movements, volume changes, and technical indicators.

Market Capitalization

The market capitalization of the immuno-oncology group, on average, stands at $563.3 million. This figure highlights the relatively moderate size of the companies within this specialized sector. Among these companies, AnaptysBio (ANAB) leads with a market cap of $924.2 million, signifying its strong position and valuation in the market. On the other hand, Corvus Pharmaceuticals (CRVS) has the smallest market cap at $224.6 million, suggesting a more speculative and potentially high-risk profile.

Price Movements: Highs and Lows

The price movements within this group have been particularly dynamic. Over the past week, the average price growth across all the stocks was 1.47%. However, the monthly price growth was significantly higher, averaging 42.58%, and the quarterly price growth was 49.25%. These figures indicate a sector that is experiencing rapid price fluctuations, which could be driven by clinical trial results, regulatory approvals, or market speculation.

  • Corvus Pharmaceuticals (CRVS): CRVS has been the standout performer in terms of price appreciation, with a weekly growth of +20.07%. This robust increase positions CRVS as a top gainer in the penny stock category, rising +17.34% in just one week. However, it's worth noting that earlier this year, CRVS also experienced significant volatility, with a notable -17.11% decline in mid-March.

  • AnaptysBio (ANAB): ANAB had a remarkable +26.9% price jump in early May, which has contributed to its strong performance over the quarter. However, recent indicators suggest a potential reversal, as the RSI oscillator has moved out of the overbought zone, which could indicate a downturn.

  • iTeos Therapeutics (ITOS): ITOS has faced some challenges, with the stock seeing a -14.23% decline, making it the biggest loser in the group. Despite this, the Aroon Indicator suggests a bullish signal, indicating that ITOS may be poised for a rebound.

Volume Trends

Volume trends across the immuno-oncology group have been notably high, reflecting strong investor interest and market activity.

  • iTeos Therapeutics (ITOS): ITOS saw an extraordinary increase in trading volume, with a one-day spike of 298% above the 65-Day Volume Moving Average. This surge could be an indication of increased investor interest or significant market events that prompted more active trading.

  • Corvus Pharmaceuticals (CRVS): CRVS experienced a sustained increase in trading volume, with five consecutive days of rising volume, averaging a daily gain of 211%. This sustained increase suggests ongoing investor attention and possibly institutional buying.

  • AnaptysBio (ANAB): ANAB also saw a significant volume increase, with a record-breaking one-day growth of 320% above the 65-Day Volume Moving Average. This sharp rise could indicate heightened interest or market-moving news that attracted traders to the stock.

Related Ticker: CRVS, ANAB, ITOS

CRVS saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for CRVS moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 53 similar instances where the indicator exited the overbought zone. In of the 53 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CRVS moved out of overbought territory on September 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for CRVS turned negative on September 12, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRVS broke above its upper Bollinger Band on September 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 13, 2025. You may want to consider a long position or call options on CRVS as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for CRVS moved above the 200-day moving average on September 10, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 137 cases where CRVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.330) is normal, around the industry mean (20.568). P/E Ratio (0.000) is within average values for comparable stocks, (53.310). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.111). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (333.018).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.89B. The market cap for tickers in the group ranges from 31.65 to 100.34B. VRTX holds the highest valuation in this group at 100.34B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 36%. NDTP experienced the highest price growth at 1,681%, while ATYR experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 90%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 82
Price Growth Rating: 57
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CRVS showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a provider of anticancer immuno-oncology drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
863 Mitten Road
Phone
+1 650 900-4520
Employees
28
Web
https://www.corvuspharma.com
Interact to see
Advertisement